FUNDAMENTALS · Fundamentals · US Healthcare

PTC Therapeutics (PTCT) Fundamentals 2026 — Revenue Analysis | SniperIQ

PTC Therapeutics (PTCT) is a US-listed Healthcare company in Biotechnology with a market capitalization of $6.5B, trading at $77.92 on the NASDAQ. This SniperIQ fundamentals page covers PTC Therapeutics's valuation, profitability (net margin -22.6%), revenue (

.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$6.5B
Net Margin-22.6%
Revenue (FY25)
.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is PTC Therapeutics's market cap?

PTC Therapeutics (PTCT) has a market capitalization of approximately $6.5B, trading at $77.92 on the NASDAQ. Market cap moves with the live share price.

How profitable is PTC Therapeutics?

PTC Therapeutics runs a net profit margin of -22.6%, a gross margin of 77.8%, and an operating margin of -8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does PTC Therapeutics generate?

PTC Therapeutics reported revenue of

.7B for fiscal year 2025, with net income of $683M and earnings per share (EPS) of 8.58. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does PTC Therapeutics pay a dividend?

PTC Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is PTC Therapeutics financially healthy?

PTC Therapeutics carries a debt-to-equity ratio of -2.19x and a current ratio of 2.44x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is PTC Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PTC Therapeutics (PTCT) the key facts are: market cap $6.5B, revenue

.7B, 52-week range 43.175-90.87. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track PTC Therapeutics's full fundamentals live

Get PTC Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.